BridgeMD
Tests treatment safety and results for Advanced Solid Tumors
Official title A Study to Assess Safety, Tolerability and Drug Levels of Navlimetostat (BMS-986504) in Participants With Advanced Solid Tumors
ClinicalTrials.gov ID: NCT07077434
What this study is testing
What is BMS-986504?
BMS-986504 is an investigational medicine, being studied as a potential treatment for advanced solid tumors.
Also referred to as MRTX1719.
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- The purpose of this study is to evaluate the safety, tolerability and drug levels of Navlimetostat (BMS-986504) in participants with advanced solid tumors.
- Phase 1: an early, usually small safety study
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older
You may be able to join if
- Participants must have histologically confirmed diagnosis of a solid tumor malignancy with homozygous MTAP deletion or MTAP loss detected in tumor...
- Participants must have unresectable or metastatic disease not amenable to curative therapies after progression on prior therapies at the time of...
- Participants must have Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
- Participants must have presence of at least one measurable tumor lesion per RECIST 1.1 at baseline.
You likely can't join if
- Participants must not have prior treatment with a Protein arginine methyltransferase 5 (PRMT5) or Methionine adenosyltransferase 2A (MAT2A) inhibitor.
- Participants must not have active brain metastases or carcinomatous meningitis.
- Participants must not have a history of gastrointestinal disease or other gastrointestinal conditions (e.g., uncontrolled nausea, vomiting...
- Participants must not have known severe hypersensitivity to study treatment and/or any of its excipients.
- Other protocol-defined Inclusion/Exclusion criteria apply.
The study team makes the final eligibility decision.
Where it's taking place
- Beijing, Beijing Municipality, China
- Fuzhou, Fujian, China
- Guangzhou, Guangdong, China
- Shenzhen, Guangdong, China
- Harbin, Heilongjiang, China
- Xinxiang, Henan, China
- Jinan, Shandong, China
- Tianjin, Tianjin Municipality, China
- Yokohama, Kanagawa, Japan
- Sunto-gun, Shizuoka, Japan
- Chuo-ku, Tokyo, Japan
- Koto-ku, Tokyo, Japan
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Beijing, Beijing Municipality, China; Fuzhou, Fujian, China; Guangzhou, Guangdong, China; Shenzhen, Guangdong, China; Harbin, Heilongjiang, China; Xinxiang, Henan, China and 6 more location(s). Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.